| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart-Assist Devices | 64 | 2026 | 568 | 7.240 |
Why?
|
| Heart Failure | 62 | 2026 | 2323 | 4.260 |
Why?
|
| Heart Transplantation | 28 | 2026 | 673 | 3.640 |
Why?
|
| Cardiac Surgical Procedures | 37 | 2025 | 606 | 3.540 |
Why?
|
| Coronary Artery Bypass | 25 | 2026 | 265 | 2.540 |
Why?
|
| Thoracic Surgery | 19 | 2026 | 144 | 2.460 |
Why?
|
| Aortic Valve | 29 | 2023 | 364 | 2.020 |
Why?
|
| Heart Valve Prosthesis Implantation | 12 | 2022 | 197 | 1.980 |
Why?
|
| Heart | 27 | 2023 | 625 | 1.800 |
Why?
|
| Aortic Valve Stenosis | 20 | 2023 | 255 | 1.770 |
Why?
|
| Spinal Cord Ischemia | 14 | 2022 | 60 | 1.630 |
Why?
|
| Postoperative Complications | 37 | 2025 | 2939 | 1.450 |
Why?
|
| Reperfusion Injury | 17 | 2021 | 295 | 1.390 |
Why?
|
| Aorta, Thoracic | 12 | 2025 | 283 | 1.260 |
Why?
|
| Mitral Valve Insufficiency | 8 | 2022 | 68 | 1.230 |
Why?
|
| Heart Ventricles | 12 | 2024 | 750 | 1.220 |
Why?
|
| Myocardium | 35 | 2026 | 927 | 1.130 |
Why?
|
| Ischemic Preconditioning, Myocardial | 20 | 2001 | 35 | 1.110 |
Why?
|
| Mitral Valve | 7 | 2022 | 94 | 1.070 |
Why?
|
| Transcatheter Aortic Valve Replacement | 8 | 2025 | 153 | 1.060 |
Why?
|
| Humans | 255 | 2026 | 144298 | 1.040 |
Why?
|
| Toll-Like Receptor 4 | 13 | 2017 | 276 | 1.010 |
Why?
|
| Tissue and Organ Procurement | 8 | 2024 | 341 | 1.000 |
Why?
|
| Cardiology | 12 | 2020 | 359 | 1.000 |
Why?
|
| Myocardial Ischemia | 22 | 2019 | 284 | 0.890 |
Why?
|
| Societies, Medical | 18 | 2023 | 890 | 0.810 |
Why?
|
| Cardiopulmonary Bypass | 11 | 2019 | 216 | 0.800 |
Why?
|
| Heart Diseases | 6 | 2019 | 341 | 0.780 |
Why?
|
| Ventricular Dysfunction, Left | 7 | 2020 | 392 | 0.770 |
Why?
|
| Treatment Outcome | 46 | 2026 | 11713 | 0.760 |
Why?
|
| Coronary Disease | 13 | 2020 | 381 | 0.760 |
Why?
|
| Calcinosis | 10 | 2017 | 234 | 0.750 |
Why?
|
| American Heart Association | 10 | 2020 | 356 | 0.750 |
Why?
|
| Aged | 89 | 2026 | 25901 | 0.740 |
Why?
|
| Male | 179 | 2026 | 72263 | 0.740 |
Why?
|
| Stroke | 15 | 2024 | 1259 | 0.730 |
Why?
|
| Tissue Donors | 6 | 2024 | 412 | 0.730 |
Why?
|
| Aortic Aneurysm | 4 | 2017 | 70 | 0.720 |
Why?
|
| Shock, Cardiogenic | 4 | 2020 | 64 | 0.710 |
Why?
|
| Coronary Artery Bypass, Off-Pump | 5 | 2017 | 16 | 0.700 |
Why?
|
| Periodicals as Topic | 2 | 2015 | 204 | 0.700 |
Why?
|
| Osteogenesis | 8 | 2017 | 207 | 0.680 |
Why?
|
| Surgeons | 6 | 2026 | 341 | 0.680 |
Why?
|
| Middle Aged | 102 | 2026 | 35892 | 0.680 |
Why?
|
| Travel | 2 | 2023 | 135 | 0.670 |
Why?
|
| Survival Rate | 19 | 2026 | 2081 | 0.650 |
Why?
|
| Myocardial Reperfusion Injury | 13 | 2015 | 137 | 0.630 |
Why?
|
| Saphenous Vein | 3 | 2019 | 35 | 0.630 |
Why?
|
| Mammary Arteries | 1 | 2019 | 8 | 0.580 |
Why?
|
| Registries | 9 | 2026 | 2389 | 0.580 |
Why?
|
| Prosthesis Design | 10 | 2024 | 355 | 0.580 |
Why?
|
| Pediatric Obesity | 2 | 2025 | 636 | 0.580 |
Why?
|
| Myocardial Contraction | 15 | 2011 | 287 | 0.570 |
Why?
|
| Female | 117 | 2026 | 78137 | 0.570 |
Why?
|
| Vena Cava, Superior | 1 | 2018 | 25 | 0.560 |
Why?
|
| Erythropoietin | 5 | 2018 | 100 | 0.560 |
Why?
|
| Heart Valve Diseases | 4 | 2021 | 150 | 0.550 |
Why?
|
| Medicare | 5 | 2023 | 888 | 0.550 |
Why?
|
| Extracorporeal Membrane Oxygenation | 4 | 2021 | 383 | 0.550 |
Why?
|
| Aortic Rupture | 1 | 2018 | 27 | 0.540 |
Why?
|
| Aortic Diseases | 4 | 2021 | 124 | 0.540 |
Why?
|
| Spinal Cord Injuries | 5 | 2021 | 240 | 0.530 |
Why?
|
| United States | 41 | 2026 | 15979 | 0.530 |
Why?
|
| Spinal Cord | 7 | 2018 | 383 | 0.520 |
Why?
|
| Heart Valve Prosthesis | 10 | 2021 | 129 | 0.520 |
Why?
|
| Receptors, Erythropoietin | 4 | 2018 | 21 | 0.520 |
Why?
|
| Anesthesiology | 3 | 2018 | 176 | 0.520 |
Why?
|
| Coronary Artery Disease | 6 | 2026 | 743 | 0.510 |
Why?
|
| Diabetes Mellitus | 3 | 2023 | 1075 | 0.500 |
Why?
|
| Critical Care | 2 | 2022 | 695 | 0.500 |
Why?
|
| Risk Assessment | 18 | 2024 | 3680 | 0.500 |
Why?
|
| Quality Improvement | 5 | 2023 | 1287 | 0.490 |
Why?
|
| Diazoxide | 4 | 2021 | 21 | 0.490 |
Why?
|
| Hospital Mortality | 12 | 2020 | 1028 | 0.490 |
Why?
|
| Paraplegia | 7 | 2022 | 60 | 0.490 |
Why?
|
| Lung Transplantation | 6 | 2019 | 329 | 0.480 |
Why?
|
| Adult | 71 | 2026 | 40408 | 0.480 |
Why?
|
| Atrial Fibrillation | 6 | 2019 | 551 | 0.480 |
Why?
|
| Propensity Score | 5 | 2026 | 371 | 0.470 |
Why?
|
| Kidney | 1 | 2024 | 1493 | 0.470 |
Why?
|
| Retrospective Studies | 37 | 2026 | 17104 | 0.460 |
Why?
|
| Quality Assurance, Health Care | 6 | 2024 | 341 | 0.460 |
Why?
|
| Resource Allocation | 2 | 2020 | 52 | 0.460 |
Why?
|
| Heart Arrest | 3 | 2022 | 405 | 0.460 |
Why?
|
| Time Factors | 38 | 2026 | 7128 | 0.440 |
Why?
|
| Protein Kinase C | 10 | 2017 | 249 | 0.440 |
Why?
|
| Health Care Rationing | 1 | 2015 | 56 | 0.420 |
Why?
|
| Models, Statistical | 5 | 2021 | 675 | 0.420 |
Why?
|
| Thrombosis | 9 | 2020 | 395 | 0.420 |
Why?
|
| Physicians, Women | 2 | 2026 | 88 | 0.420 |
Why?
|
| Follow-Up Studies | 26 | 2026 | 5404 | 0.410 |
Why?
|
| Drug Dosage Calculations | 1 | 2014 | 27 | 0.410 |
Why?
|
| Kaplan-Meier Estimate | 13 | 2022 | 966 | 0.410 |
Why?
|
| Thoracic Surgical Procedures | 3 | 2022 | 95 | 0.400 |
Why?
|
| Frail Elderly | 2 | 2013 | 134 | 0.400 |
Why?
|
| Myocardial Revascularization | 3 | 2020 | 84 | 0.390 |
Why?
|
| Databases, Factual | 12 | 2023 | 1489 | 0.390 |
Why?
|
| Aortic Valve Insufficiency | 5 | 2022 | 43 | 0.390 |
Why?
|
| Vancomycin | 1 | 2014 | 94 | 0.380 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2014 | 134 | 0.370 |
Why?
|
| Macrophages, Peritoneal | 2 | 2015 | 89 | 0.360 |
Why?
|
| Toll-Like Receptor 2 | 6 | 2017 | 126 | 0.360 |
Why?
|
| Myocytes, Cardiac | 5 | 2026 | 538 | 0.360 |
Why?
|
| Defibrillators, Implantable | 5 | 2025 | 381 | 0.360 |
Why?
|
| Lipoproteins, LDL | 3 | 2012 | 119 | 0.360 |
Why?
|
| Anesthesia | 1 | 2016 | 257 | 0.360 |
Why?
|
| Atherosclerosis | 2 | 2018 | 408 | 0.360 |
Why?
|
| Physicians | 1 | 2021 | 948 | 0.360 |
Why?
|
| Gait | 2 | 2016 | 312 | 0.360 |
Why?
|
| Organ Preservation | 5 | 2024 | 125 | 0.360 |
Why?
|
| Foam Cells | 2 | 2011 | 17 | 0.350 |
Why?
|
| Percutaneous Coronary Intervention | 4 | 2022 | 547 | 0.330 |
Why?
|
| Lymphoma | 2 | 2023 | 233 | 0.320 |
Why?
|
| Ventricular Function, Right | 3 | 2026 | 296 | 0.320 |
Why?
|
| Aging | 5 | 2017 | 1935 | 0.320 |
Why?
|
| NF-kappa B | 10 | 2017 | 656 | 0.320 |
Why?
|
| Surgical Wound Infection | 1 | 2014 | 329 | 0.320 |
Why?
|
| Potassium Channels | 4 | 2021 | 145 | 0.320 |
Why?
|
| United States Food and Drug Administration | 1 | 2011 | 204 | 0.320 |
Why?
|
| Cardiovascular Diseases | 5 | 2019 | 2170 | 0.310 |
Why?
|
| Social Determinants of Health | 2 | 2025 | 304 | 0.310 |
Why?
|
| Clinical Competence | 6 | 2020 | 1236 | 0.300 |
Why?
|
| Ventricular Dysfunction, Right | 2 | 2026 | 248 | 0.300 |
Why?
|
| Equipment Failure | 5 | 2020 | 115 | 0.290 |
Why?
|
| Aortic Aneurysm, Thoracic | 2 | 2022 | 138 | 0.290 |
Why?
|
| Heart Defects, Congenital | 2 | 2015 | 896 | 0.290 |
Why?
|
| Arterial Occlusive Diseases | 2 | 2014 | 89 | 0.290 |
Why?
|
| Reoperation | 10 | 2023 | 623 | 0.290 |
Why?
|
| Signal Transduction | 20 | 2021 | 5182 | 0.290 |
Why?
|
| Cardiomyopathy, Dilated | 4 | 2019 | 355 | 0.290 |
Why?
|
| Adenosine | 8 | 2023 | 255 | 0.290 |
Why?
|
| Animals | 69 | 2026 | 37800 | 0.280 |
Why?
|
| Internal Mammary-Coronary Artery Anastomosis | 1 | 2008 | 3 | 0.280 |
Why?
|
| Length of Stay | 7 | 2025 | 1338 | 0.280 |
Why?
|
| Chemokines | 4 | 2015 | 217 | 0.270 |
Why?
|
| Blood Vessel Prosthesis Implantation | 2 | 2022 | 228 | 0.270 |
Why?
|
| California | 3 | 2025 | 471 | 0.270 |
Why?
|
| Risk Factors | 21 | 2026 | 10783 | 0.270 |
Why?
|
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 2 | 2023 | 32 | 0.260 |
Why?
|
| Myofibroblasts | 3 | 2017 | 142 | 0.260 |
Why?
|
| Cells, Cultured | 17 | 2021 | 4102 | 0.260 |
Why?
|
| Calcium | 10 | 2023 | 1174 | 0.260 |
Why?
|
| Glucuronidase | 2 | 2017 | 25 | 0.260 |
Why?
|
| Bone Morphogenetic Protein 2 | 7 | 2017 | 76 | 0.260 |
Why?
|
| Cardiomyopathies | 4 | 2019 | 334 | 0.240 |
Why?
|
| Mice, Inbred C57BL | 18 | 2021 | 5954 | 0.240 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2007 | 250 | 0.240 |
Why?
|
| Aged, 80 and over | 17 | 2025 | 8265 | 0.230 |
Why?
|
| Rats, Sprague-Dawley | 31 | 2026 | 2512 | 0.230 |
Why?
|
| Mice | 24 | 2023 | 18218 | 0.230 |
Why?
|
| Advisory Committees | 5 | 2019 | 228 | 0.230 |
Why?
|
| Matrix Metalloproteinases | 2 | 2017 | 95 | 0.230 |
Why?
|
| In Vitro Techniques | 18 | 2009 | 1041 | 0.220 |
Why?
|
| Organ Transplantation | 4 | 2024 | 247 | 0.220 |
Why?
|
| Acute Kidney Injury | 5 | 2020 | 869 | 0.220 |
Why?
|
| Adenosine Triphosphate | 6 | 2022 | 500 | 0.220 |
Why?
|
| Disease Models, Animal | 12 | 2021 | 4525 | 0.220 |
Why?
|
| Up-Regulation | 7 | 2018 | 847 | 0.220 |
Why?
|
| Tissue and Organ Harvesting | 2 | 2024 | 75 | 0.220 |
Why?
|
| Perfusion | 6 | 2024 | 248 | 0.220 |
Why?
|
| Prosthesis-Related Infections | 2 | 2020 | 98 | 0.210 |
Why?
|
| Patient Safety | 3 | 2019 | 351 | 0.210 |
Why?
|
| Creatine Kinase | 15 | 1998 | 72 | 0.210 |
Why?
|
| Organizational Culture | 1 | 2026 | 160 | 0.210 |
Why?
|
| Ultrasonography, Interventional | 2 | 2020 | 159 | 0.210 |
Why?
|
| Prospective Studies | 15 | 2022 | 7972 | 0.210 |
Why?
|
| Ischemic Preconditioning | 2 | 2001 | 47 | 0.210 |
Why?
|
| Echocardiography, Transesophageal | 4 | 2014 | 132 | 0.210 |
Why?
|
| Cardiovascular Surgical Procedures | 2 | 2014 | 30 | 0.210 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2025 | 63 | 0.210 |
Why?
|
| Calcium-Binding Proteins | 4 | 2022 | 220 | 0.200 |
Why?
|
| Assisted Circulation | 2 | 2021 | 26 | 0.200 |
Why?
|
| Organ Preservation Solutions | 1 | 2023 | 46 | 0.200 |
Why?
|
| Waiting Lists | 4 | 2021 | 263 | 0.200 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2019 | 579 | 0.200 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2021 | 294 | 0.200 |
Why?
|
| Hypothermia, Induced | 2 | 2022 | 94 | 0.200 |
Why?
|
| Ventricular Function, Left | 8 | 2020 | 535 | 0.200 |
Why?
|
| Inflammation | 7 | 2017 | 2862 | 0.200 |
Why?
|
| Neuroprotective Agents | 2 | 2018 | 143 | 0.200 |
Why?
|
| Workplace | 1 | 2026 | 270 | 0.200 |
Why?
|
| Primary Graft Dysfunction | 1 | 2023 | 33 | 0.200 |
Why?
|
| Alternative Splicing | 1 | 2026 | 245 | 0.200 |
Why?
|
| Pulmonary Valve | 3 | 2009 | 100 | 0.200 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 3 | 1 | 2023 | 8 | 0.190 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2026 | 196 | 0.190 |
Why?
|
| Incidence | 7 | 2025 | 2886 | 0.190 |
Why?
|
| Rats | 34 | 2026 | 5553 | 0.190 |
Why?
|
| Myofibrils | 2 | 2021 | 47 | 0.190 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2024 | 136 | 0.190 |
Why?
|
| Circulatory Arrest, Deep Hypothermia Induced | 2 | 2022 | 27 | 0.190 |
Why?
|
| Anti-Bacterial Agents | 1 | 2014 | 1920 | 0.190 |
Why?
|
| Mentors | 1 | 2025 | 214 | 0.190 |
Why?
|
| Practice Guidelines as Topic | 3 | 2022 | 1565 | 0.190 |
Why?
|
| Data Accuracy | 2 | 2020 | 65 | 0.190 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2023 | 57 | 0.190 |
Why?
|
| Gene Expression Regulation | 7 | 2019 | 2589 | 0.190 |
Why?
|
| Lipopolysaccharides | 8 | 2017 | 854 | 0.190 |
Why?
|
| Cell Culture Techniques | 3 | 2021 | 372 | 0.190 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 1762 | 0.190 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 1 | 2022 | 46 | 0.190 |
Why?
|
| Elective Surgical Procedures | 3 | 2013 | 199 | 0.190 |
Why?
|
| Digestive System Surgical Procedures | 2 | 2013 | 110 | 0.180 |
Why?
|
| Microglia | 3 | 2013 | 269 | 0.180 |
Why?
|
| Respiratory Insufficiency | 2 | 2023 | 323 | 0.180 |
Why?
|
| Decision Making | 4 | 2018 | 972 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2017 | 435 | 0.180 |
Why?
|
| Core Binding Factor Alpha 1 Subunit | 5 | 2017 | 45 | 0.180 |
Why?
|
| Heart Injuries | 2 | 2020 | 42 | 0.180 |
Why?
|
| Succinic Acid | 2 | 2019 | 42 | 0.180 |
Why?
|
| Adaptation, Physiological | 9 | 2000 | 566 | 0.180 |
Why?
|
| Technology Transfer | 1 | 2021 | 9 | 0.170 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2023 | 101 | 0.170 |
Why?
|
| Developmental Disabilities | 1 | 2024 | 279 | 0.170 |
Why?
|
| Geriatric Assessment | 2 | 2013 | 233 | 0.170 |
Why?
|
| Tumor Necrosis Factor-alpha | 7 | 2013 | 1206 | 0.170 |
Why?
|
| Cation Transport Proteins | 1 | 2022 | 118 | 0.170 |
Why?
|
| Decision Support Techniques | 2 | 2018 | 460 | 0.170 |
Why?
|
| Ischemia | 6 | 2021 | 421 | 0.170 |
Why?
|
| Heart Arrest, Induced | 4 | 1997 | 26 | 0.170 |
Why?
|
| Specialties, Surgical | 1 | 2022 | 82 | 0.170 |
Why?
|
| Reactive Oxygen Species | 2 | 2022 | 601 | 0.170 |
Why?
|
| Mice, Inbred C3H | 5 | 2014 | 251 | 0.170 |
Why?
|
| Echocardiography, Three-Dimensional | 2 | 2012 | 71 | 0.170 |
Why?
|
| Thorax | 1 | 2021 | 50 | 0.170 |
Why?
|
| Heart Atria | 4 | 2014 | 140 | 0.160 |
Why?
|
| Cell Differentiation | 3 | 2021 | 2033 | 0.160 |
Why?
|
| Leadership | 1 | 2025 | 399 | 0.160 |
Why?
|
| Vascular Grafting | 1 | 2020 | 15 | 0.160 |
Why?
|
| Endovascular Procedures | 1 | 2025 | 385 | 0.160 |
Why?
|
| Radial Artery | 2 | 2019 | 70 | 0.160 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2021 | 124 | 0.160 |
Why?
|
| Disease Management | 3 | 2019 | 647 | 0.160 |
Why?
|
| Evidence-Based Medicine | 2 | 2014 | 732 | 0.160 |
Why?
|
| Aortography | 2 | 2019 | 52 | 0.150 |
Why?
|
| Sternotomy | 1 | 2020 | 25 | 0.150 |
Why?
|
| Vascular Remodeling | 2 | 2021 | 203 | 0.150 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 5 | 1997 | 45 | 0.150 |
Why?
|
| Coronary Vessels | 4 | 2018 | 246 | 0.150 |
Why?
|
| Preceptorship | 2 | 2017 | 63 | 0.150 |
Why?
|
| Cardiac Catheterization | 3 | 2016 | 554 | 0.150 |
Why?
|
| Rupture | 1 | 2020 | 91 | 0.150 |
Why?
|
| Tricuspid Valve | 1 | 2020 | 41 | 0.150 |
Why?
|
| Child Development | 1 | 2024 | 482 | 0.150 |
Why?
|
| Prognosis | 10 | 2019 | 4293 | 0.150 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2021 | 140 | 0.150 |
Why?
|
| STAT3 Transcription Factor | 2 | 2018 | 205 | 0.150 |
Why?
|
| Health Expenditures | 1 | 2021 | 194 | 0.150 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2021 | 175 | 0.150 |
Why?
|
| Emergency Treatment | 1 | 2020 | 124 | 0.150 |
Why?
|
| Arrhythmias, Cardiac | 3 | 2014 | 355 | 0.150 |
Why?
|
| Data Mining | 1 | 2020 | 115 | 0.150 |
Why?
|
| HSC70 Heat-Shock Proteins | 2 | 2009 | 4 | 0.140 |
Why?
|
| Lamin Type A | 1 | 2019 | 50 | 0.140 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2019 | 63 | 0.140 |
Why?
|
| Burnout, Professional | 1 | 2026 | 483 | 0.140 |
Why?
|
| Comparative Effectiveness Research | 1 | 2020 | 167 | 0.140 |
Why?
|
| Kidney Diseases | 1 | 2023 | 427 | 0.140 |
Why?
|
| Multicenter Studies as Topic | 2 | 2022 | 408 | 0.140 |
Why?
|
| von Willebrand Factor | 1 | 2019 | 85 | 0.140 |
Why?
|
| Femoral Vein | 1 | 2019 | 38 | 0.140 |
Why?
|
| Atrioventricular Block | 1 | 2019 | 44 | 0.140 |
Why?
|
| Aspirin | 2 | 2020 | 400 | 0.140 |
Why?
|
| Survival Analysis | 7 | 2020 | 1368 | 0.140 |
Why?
|
| Minimally Invasive Surgical Procedures | 3 | 2019 | 188 | 0.140 |
Why?
|
| Creatinine | 1 | 2020 | 509 | 0.140 |
Why?
|
| Walking Speed | 1 | 2018 | 51 | 0.140 |
Why?
|
| Intracranial Hemorrhages | 1 | 2019 | 100 | 0.140 |
Why?
|
| Heart Neoplasms | 2 | 2012 | 56 | 0.140 |
Why?
|
| Quality of Health Care | 1 | 2023 | 692 | 0.130 |
Why?
|
| Phenylephrine | 7 | 2021 | 74 | 0.130 |
Why?
|
| Vascular Patency | 2 | 2015 | 121 | 0.130 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2021 | 269 | 0.130 |
Why?
|
| Thrombocytopenia | 1 | 2019 | 202 | 0.130 |
Why?
|
| Equipment Design | 6 | 2018 | 522 | 0.130 |
Why?
|
| Toll-Like Receptors | 2 | 2015 | 193 | 0.130 |
Why?
|
| Dexmedetomidine | 2 | 2014 | 44 | 0.130 |
Why?
|
| Catheterization | 2 | 2018 | 183 | 0.130 |
Why?
|
| Receptors, Adrenergic, alpha | 1 | 1997 | 19 | 0.130 |
Why?
|
| ADAMTS5 Protein | 1 | 2017 | 4 | 0.130 |
Why?
|
| Cytokines | 7 | 2017 | 2043 | 0.130 |
Why?
|
| Warm Ischemia | 2 | 2022 | 18 | 0.130 |
Why?
|
| Phylogeny | 1 | 2022 | 1020 | 0.130 |
Why?
|
| Mitochondrial Proteins | 1 | 2019 | 262 | 0.130 |
Why?
|
| Neuroprotection | 1 | 2017 | 45 | 0.130 |
Why?
|
| Internship and Residency | 2 | 2020 | 1261 | 0.130 |
Why?
|
| Neurotrophin 3 | 1 | 2017 | 10 | 0.130 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 3 | 2020 | 919 | 0.130 |
Why?
|
| Odds Ratio | 5 | 2017 | 1076 | 0.130 |
Why?
|
| American Medical Association | 2 | 2013 | 19 | 0.130 |
Why?
|
| Extracellular Matrix | 1 | 2021 | 552 | 0.130 |
Why?
|
| Cell Transdifferentiation | 1 | 2017 | 31 | 0.130 |
Why?
|
| Nicorandil | 3 | 2021 | 11 | 0.130 |
Why?
|
| Receptor, trkA | 1 | 2017 | 18 | 0.130 |
Why?
|
| Magnets | 1 | 2017 | 21 | 0.130 |
Why?
|
| Sulfonylurea Compounds | 1 | 1997 | 51 | 0.130 |
Why?
|
| Interleukins | 2 | 2017 | 248 | 0.130 |
Why?
|
| SOX9 Transcription Factor | 1 | 2017 | 27 | 0.130 |
Why?
|
| Postoperative Care | 2 | 2017 | 286 | 0.130 |
Why?
|
| Phosphates | 2 | 2017 | 177 | 0.130 |
Why?
|
| Analysis of Variance | 8 | 2019 | 1300 | 0.130 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 1055 | 0.130 |
Why?
|
| Cyclin D1 | 1 | 2017 | 63 | 0.130 |
Why?
|
| Down-Regulation | 2 | 2017 | 613 | 0.120 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2018 | 164 | 0.120 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 358 | 0.120 |
Why?
|
| Cohort Studies | 8 | 2023 | 5948 | 0.120 |
Why?
|
| Cause of Death | 3 | 2026 | 463 | 0.120 |
Why?
|
| Coronary Vasospasm | 1 | 2016 | 8 | 0.120 |
Why?
|
| Tissue Banks | 1 | 2016 | 17 | 0.120 |
Why?
|
| Osteoblasts | 1 | 2017 | 146 | 0.120 |
Why?
|
| Endotoxemia | 1 | 2017 | 86 | 0.120 |
Why?
|
| Amiodarone | 1 | 2016 | 31 | 0.120 |
Why?
|
| Cardiovascular Agents | 2 | 1997 | 165 | 0.120 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2018 | 263 | 0.120 |
Why?
|
| Multidetector Computed Tomography | 1 | 2016 | 40 | 0.120 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 942 | 0.120 |
Why?
|
| Biomedical Research | 2 | 2020 | 712 | 0.120 |
Why?
|
| Receptors, Adrenergic, beta-1 | 1 | 2015 | 24 | 0.120 |
Why?
|
| Morbidity | 2 | 2021 | 322 | 0.120 |
Why?
|
| Disease-Free Survival | 4 | 2019 | 768 | 0.110 |
Why?
|
| Intercellular Adhesion Molecule-1 | 3 | 2014 | 129 | 0.110 |
Why?
|
| Quality of Life | 6 | 2025 | 3180 | 0.110 |
Why?
|
| Accidental Falls | 2 | 2020 | 221 | 0.110 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2020 | 495 | 0.110 |
Why?
|
| Case-Control Studies | 7 | 2017 | 3595 | 0.110 |
Why?
|
| Access to Information | 1 | 2015 | 47 | 0.110 |
Why?
|
| Directed Tissue Donation | 1 | 2015 | 5 | 0.110 |
Why?
|
| Interleukin-6 | 3 | 2015 | 770 | 0.110 |
Why?
|
| Recombinant Proteins | 6 | 2017 | 1360 | 0.110 |
Why?
|
| Brain Ischemia | 1 | 2019 | 358 | 0.110 |
Why?
|
| Osteosarcoma | 1 | 2015 | 76 | 0.110 |
Why?
|
| Collagen | 2 | 2017 | 450 | 0.110 |
Why?
|
| Medical Staff, Hospital | 1 | 2015 | 80 | 0.110 |
Why?
|
| Costs and Cost Analysis | 3 | 2024 | 220 | 0.110 |
Why?
|
| Salmonella typhimurium | 2 | 2015 | 189 | 0.110 |
Why?
|
| Computed Tomography Angiography | 1 | 2016 | 146 | 0.110 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2015 | 117 | 0.110 |
Why?
|
| Adrenergic alpha-2 Receptor Agonists | 1 | 2014 | 25 | 0.110 |
Why?
|
| Intraoperative Complications | 1 | 2016 | 157 | 0.110 |
Why?
|
| CREB-Binding Protein | 1 | 2014 | 34 | 0.110 |
Why?
|
| Radiography, Interventional | 1 | 2016 | 128 | 0.110 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2014 | 9 | 0.110 |
Why?
|
| Confidence Intervals | 3 | 2010 | 331 | 0.110 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2015 | 194 | 0.110 |
Why?
|
| Alkaline Phosphatase | 4 | 2017 | 144 | 0.100 |
Why?
|
| Specimen Handling | 1 | 2016 | 186 | 0.100 |
Why?
|
| Recovery of Function | 2 | 2026 | 715 | 0.100 |
Why?
|
| Patient Participation | 1 | 2018 | 428 | 0.100 |
Why?
|
| Bioprosthesis | 4 | 2020 | 39 | 0.100 |
Why?
|
| Young Adult | 10 | 2026 | 14092 | 0.100 |
Why?
|
| Infusions, Parenteral | 1 | 2014 | 46 | 0.100 |
Why?
|
| Cardiac Pacing, Artificial | 2 | 2009 | 84 | 0.100 |
Why?
|
| Preoperative Care | 2 | 2013 | 378 | 0.100 |
Why?
|
| Motor Activity | 3 | 2014 | 723 | 0.100 |
Why?
|
| Pneumonectomy | 3 | 2008 | 167 | 0.100 |
Why?
|
| DNA Methylation | 1 | 2019 | 664 | 0.100 |
Why?
|
| Phagocytosis | 1 | 2015 | 294 | 0.100 |
Why?
|
| Intention to Treat Analysis | 3 | 2019 | 79 | 0.100 |
Why?
|
| Mitochondria | 1 | 2020 | 981 | 0.100 |
Why?
|
| Endotoxins | 5 | 1997 | 217 | 0.100 |
Why?
|
| Suture Techniques | 3 | 2010 | 132 | 0.100 |
Why?
|
| Kidney Failure, Chronic | 1 | 2019 | 596 | 0.100 |
Why?
|
| Phosphorylation | 6 | 2018 | 1702 | 0.100 |
Why?
|
| Osteopontin | 2 | 2012 | 34 | 0.100 |
Why?
|
| Actins | 4 | 2018 | 421 | 0.100 |
Why?
|
| Brain Death | 2 | 2024 | 58 | 0.100 |
Why?
|
| Information Dissemination | 1 | 2015 | 222 | 0.100 |
Why?
|
| Bone Neoplasms | 1 | 2015 | 254 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2017 | 832 | 0.100 |
Why?
|
| Biglycan | 1 | 2012 | 3 | 0.090 |
Why?
|
| Fellowships and Scholarships | 1 | 2017 | 355 | 0.090 |
Why?
|
| Prosthesis Implantation | 1 | 2014 | 153 | 0.090 |
Why?
|
| Calcium Channels | 4 | 2022 | 155 | 0.090 |
Why?
|
| Receptors, Purinergic P1 | 3 | 1997 | 30 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2020 | 1359 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 2 | 2012 | 171 | 0.090 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2015 | 265 | 0.090 |
Why?
|
| Pulmonary Emphysema | 1 | 2015 | 275 | 0.090 |
Why?
|
| Astrocytes | 1 | 2014 | 228 | 0.090 |
Why?
|
| Apoptosis | 2 | 2018 | 2395 | 0.090 |
Why?
|
| Sarcoplasmic Reticulum | 3 | 2023 | 40 | 0.090 |
Why?
|
| Receptor, Notch1 | 1 | 2012 | 63 | 0.090 |
Why?
|
| Sex Factors | 7 | 2026 | 2103 | 0.090 |
Why?
|
| Neurons | 2 | 2020 | 1637 | 0.090 |
Why?
|
| Research Report | 3 | 2019 | 86 | 0.090 |
Why?
|
| Immunohistochemistry | 6 | 2021 | 1699 | 0.090 |
Why?
|
| Body Weight | 2 | 2014 | 968 | 0.090 |
Why?
|
| Adolescent | 13 | 2026 | 22370 | 0.090 |
Why?
|
| Ventricular Remodeling | 3 | 2026 | 275 | 0.090 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2012 | 40 | 0.090 |
Why?
|
| Brain Neoplasms | 1 | 2021 | 1325 | 0.090 |
Why?
|
| Administration, Oral | 3 | 2020 | 847 | 0.090 |
Why?
|
| Vascular Stiffness | 1 | 2017 | 485 | 0.090 |
Why?
|
| Drug Administration Schedule | 1 | 2014 | 779 | 0.090 |
Why?
|
| Immunity, Innate | 2 | 2008 | 842 | 0.090 |
Why?
|
| Risk | 5 | 2020 | 910 | 0.090 |
Why?
|
| Phenotype | 7 | 2017 | 3139 | 0.090 |
Why?
|
| Staphylococcus aureus | 1 | 2015 | 452 | 0.090 |
Why?
|
| Models, Cardiovascular | 1 | 2012 | 193 | 0.090 |
Why?
|
| Death | 2 | 2022 | 130 | 0.080 |
Why?
|
| Radiation Injuries | 1 | 2012 | 149 | 0.080 |
Why?
|
| Myelitis | 1 | 2012 | 107 | 0.080 |
Why?
|
| Muscle, Smooth, Vascular | 4 | 2018 | 440 | 0.080 |
Why?
|
| Interleukin-1beta | 1 | 2013 | 390 | 0.080 |
Why?
|
| Hemodynamics | 4 | 1997 | 1113 | 0.080 |
Why?
|
| Age Factors | 8 | 2020 | 3324 | 0.080 |
Why?
|
| Mice, Mutant Strains | 1 | 2011 | 299 | 0.080 |
Why?
|
| Aorta, Abdominal | 1 | 2011 | 52 | 0.080 |
Why?
|
| Drug-Eluting Stents | 1 | 2011 | 88 | 0.080 |
Why?
|
| MicroRNAs | 1 | 2017 | 689 | 0.080 |
Why?
|
| Macrophages | 3 | 2015 | 1496 | 0.080 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2011 | 155 | 0.080 |
Why?
|
| Isoenzymes | 5 | 1997 | 297 | 0.080 |
Why?
|
| Myocarditis | 2 | 2009 | 101 | 0.080 |
Why?
|
| Prosthesis Failure | 3 | 2019 | 125 | 0.080 |
Why?
|
| Coronary Aneurysm | 1 | 2010 | 17 | 0.080 |
Why?
|
| Drug Monitoring | 1 | 2014 | 396 | 0.080 |
Why?
|
| Mice, Knockout | 5 | 2017 | 3106 | 0.080 |
Why?
|
| Blood Vessel Prosthesis | 2 | 2022 | 140 | 0.080 |
Why?
|
| Patient-Centered Care | 2 | 2014 | 540 | 0.080 |
Why?
|
| Hospitalization | 4 | 2023 | 2440 | 0.080 |
Why?
|
| Inflammation Mediators | 2 | 2013 | 503 | 0.080 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2011 | 253 | 0.080 |
Why?
|
| Smad1 Protein | 1 | 2009 | 17 | 0.080 |
Why?
|
| Mitral Valve Prolapse | 1 | 2009 | 9 | 0.080 |
Why?
|
| Severity of Illness Index | 4 | 2019 | 2917 | 0.080 |
Why?
|
| Electric Stimulation Therapy | 1 | 2010 | 62 | 0.080 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2021 | 905 | 0.070 |
Why?
|
| Immunosuppressive Agents | 2 | 2023 | 834 | 0.070 |
Why?
|
| Child | 6 | 2025 | 22562 | 0.070 |
Why?
|
| Axillary Artery | 2 | 2018 | 13 | 0.070 |
Why?
|
| Mitosporic Fungi | 1 | 2009 | 6 | 0.070 |
Why?
|
| Safety | 1 | 2011 | 354 | 0.070 |
Why?
|
| Comorbidity | 3 | 2020 | 1652 | 0.070 |
Why?
|
| Thromboembolism | 3 | 2019 | 126 | 0.070 |
Why?
|
| Automobile Driving | 1 | 2011 | 157 | 0.070 |
Why?
|
| Calcium Channel Blockers | 2 | 2000 | 165 | 0.070 |
Why?
|
| Neutrophil Infiltration | 1 | 2009 | 104 | 0.070 |
Why?
|
| Chemokine CCL2 | 1 | 2009 | 112 | 0.070 |
Why?
|
| Sequence Analysis, RNA | 2 | 2021 | 441 | 0.070 |
Why?
|
| Regression Analysis | 1 | 2011 | 997 | 0.070 |
Why?
|
| Walking | 1 | 2013 | 542 | 0.070 |
Why?
|
| Actin Cytoskeleton | 1 | 2009 | 102 | 0.070 |
Why?
|
| Glucose | 3 | 2023 | 1033 | 0.070 |
Why?
|
| Phospholipases A2 | 1 | 2008 | 79 | 0.070 |
Why?
|
| Liver Transplantation | 1 | 2015 | 826 | 0.070 |
Why?
|
| Hindlimb | 3 | 2015 | 131 | 0.070 |
Why?
|
| RNA Interference | 3 | 2017 | 472 | 0.070 |
Why?
|
| Intensive Care Units | 3 | 2020 | 912 | 0.070 |
Why?
|
| Coronary Circulation | 9 | 1998 | 133 | 0.070 |
Why?
|
| Mycoses | 1 | 2009 | 88 | 0.070 |
Why?
|
| Proportional Hazards Models | 3 | 2018 | 1322 | 0.070 |
Why?
|
| Colorado | 2 | 2019 | 4554 | 0.070 |
Why?
|
| Cell Survival | 3 | 2017 | 1092 | 0.070 |
Why?
|
| Tropomyosin | 1 | 2007 | 10 | 0.070 |
Why?
|
| Counseling | 1 | 2011 | 405 | 0.070 |
Why?
|
| Enzyme Inhibitors | 5 | 1997 | 819 | 0.070 |
Why?
|
| Pulmonary Artery | 4 | 2011 | 1124 | 0.070 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 3408 | 0.070 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2007 | 55 | 0.070 |
Why?
|
| Echocardiography | 3 | 2020 | 644 | 0.070 |
Why?
|
| Qualitative Research | 2 | 2026 | 1660 | 0.070 |
Why?
|
| Patient Readmission | 3 | 2020 | 762 | 0.070 |
Why?
|
| Exercise Test | 1 | 2010 | 626 | 0.070 |
Why?
|
| Caregivers | 1 | 2016 | 1051 | 0.070 |
Why?
|
| Hypoglycemic Agents | 1 | 1997 | 1388 | 0.070 |
Why?
|
| Brain | 1 | 2020 | 2929 | 0.070 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2007 | 49 | 0.070 |
Why?
|
| Endothelium, Vascular | 4 | 2018 | 948 | 0.070 |
Why?
|
| Fibrosis | 2 | 2021 | 547 | 0.060 |
Why?
|
| Patient Selection | 3 | 2019 | 721 | 0.060 |
Why?
|
| Glyburide | 2 | 1997 | 31 | 0.060 |
Why?
|
| HEK293 Cells | 2 | 2023 | 741 | 0.060 |
Why?
|
| Body Surface Area | 1 | 2007 | 34 | 0.060 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2007 | 68 | 0.060 |
Why?
|
| Lower Extremity | 1 | 2011 | 440 | 0.060 |
Why?
|
| Device Removal | 3 | 2017 | 142 | 0.060 |
Why?
|
| Heart Rate | 7 | 2019 | 849 | 0.060 |
Why?
|
| Sarcomeres | 2 | 2021 | 96 | 0.060 |
Why?
|
| Bayes Theorem | 2 | 2021 | 425 | 0.060 |
Why?
|
| Myosin Heavy Chains | 1 | 2007 | 183 | 0.060 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 2014 | 141 | 0.060 |
Why?
|
| Graft Survival | 2 | 2023 | 510 | 0.060 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2007 | 227 | 0.060 |
Why?
|
| Cardiac Output | 2 | 2020 | 178 | 0.060 |
Why?
|
| Hospitals, Veterans | 3 | 2002 | 258 | 0.060 |
Why?
|
| Materials Testing | 2 | 2018 | 349 | 0.060 |
Why?
|
| Aorta | 4 | 2015 | 426 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2008 | 337 | 0.060 |
Why?
|
| Coronary Angiography | 3 | 2013 | 324 | 0.060 |
Why?
|
| Norepinephrine | 2 | 1997 | 195 | 0.060 |
Why?
|
| Anastomosis, Surgical | 2 | 2019 | 161 | 0.060 |
Why?
|
| Barrett Esophagus | 1 | 2008 | 165 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2007 | 749 | 0.060 |
Why?
|
| Lung | 5 | 2011 | 4084 | 0.060 |
Why?
|
| Cryptogenic Organizing Pneumonia | 1 | 2005 | 20 | 0.060 |
Why?
|
| Hemorrhage | 4 | 1997 | 807 | 0.060 |
Why?
|
| Reimbursement Mechanisms | 2 | 2019 | 79 | 0.060 |
Why?
|
| Calcineurin Inhibitors | 1 | 2005 | 69 | 0.060 |
Why?
|
| Myocardial Reperfusion | 4 | 1998 | 57 | 0.060 |
Why?
|
| Sexism | 1 | 2026 | 69 | 0.060 |
Why?
|
| Protein Biosynthesis | 3 | 1997 | 454 | 0.050 |
Why?
|
| Nitric Oxide | 2 | 2021 | 894 | 0.050 |
Why?
|
| Heat-Shock Proteins | 2 | 2014 | 133 | 0.050 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 2024 | 73 | 0.050 |
Why?
|
| Frailty | 2 | 2018 | 199 | 0.050 |
Why?
|
| Raffinose | 1 | 2023 | 29 | 0.050 |
Why?
|
| Esophageal Neoplasms | 1 | 2008 | 345 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2011 | 1501 | 0.050 |
Why?
|
| Allopurinol | 1 | 2023 | 70 | 0.050 |
Why?
|
| Germinoma | 1 | 2003 | 10 | 0.050 |
Why?
|
| Patient Preference | 2 | 2018 | 226 | 0.050 |
Why?
|
| Career Choice | 1 | 2026 | 233 | 0.050 |
Why?
|
| Blood Pressure | 7 | 2018 | 1763 | 0.050 |
Why?
|
| Sirolimus | 1 | 2005 | 280 | 0.050 |
Why?
|
| Job Satisfaction | 1 | 2026 | 235 | 0.050 |
Why?
|
| Hydrogen-Ion Concentration | 4 | 1998 | 559 | 0.050 |
Why?
|
| Breast Neoplasms | 1 | 2016 | 2363 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2022 | 1739 | 0.050 |
Why?
|
| Vasodilation | 2 | 2016 | 520 | 0.050 |
Why?
|
| Shock | 1 | 2024 | 107 | 0.050 |
Why?
|
| Transfection | 2 | 2017 | 922 | 0.050 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 3 | 2012 | 264 | 0.050 |
Why?
|
| Phenanthridines | 3 | 1996 | 7 | 0.050 |
Why?
|
| Emergencies | 1 | 2003 | 174 | 0.050 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2022 | 66 | 0.050 |
Why?
|
| Neutrophils | 3 | 1997 | 1115 | 0.050 |
Why?
|
| Disulfides | 1 | 2022 | 94 | 0.050 |
Why?
|
| Conjunctivitis | 1 | 1982 | 30 | 0.050 |
Why?
|
| Testicular Neoplasms | 1 | 2003 | 111 | 0.050 |
Why?
|
| Herpesvirus 4, Human | 1 | 2023 | 176 | 0.040 |
Why?
|
| Matrix Metalloproteinases, Secreted | 1 | 2021 | 12 | 0.040 |
Why?
|
| ADAMTS4 Protein | 1 | 2021 | 16 | 0.040 |
Why?
|
| Long Term Adverse Effects | 1 | 2021 | 13 | 0.040 |
Why?
|
| Homeostasis | 2 | 1996 | 635 | 0.040 |
Why?
|
| Meta-Analysis as Topic | 1 | 2022 | 170 | 0.040 |
Why?
|
| Glutathione | 1 | 2023 | 364 | 0.040 |
Why?
|
| Arteriosclerosis | 2 | 1995 | 83 | 0.040 |
Why?
|
| Catheters | 1 | 2022 | 75 | 0.040 |
Why?
|
| Subclavian Artery | 2 | 2012 | 28 | 0.040 |
Why?
|
| Benzoates | 1 | 2021 | 50 | 0.040 |
Why?
|
| Body Size | 1 | 2022 | 94 | 0.040 |
Why?
|
| Calcium-Transporting ATPases | 2 | 1998 | 33 | 0.040 |
Why?
|
| Poverty | 1 | 2025 | 522 | 0.040 |
Why?
|
| ROC Curve | 2 | 2013 | 615 | 0.040 |
Why?
|
| Heart Valves | 1 | 2021 | 43 | 0.040 |
Why?
|
| Vascular Surgical Procedures | 2 | 2001 | 342 | 0.040 |
Why?
|
| RNA | 2 | 2019 | 926 | 0.040 |
Why?
|
| Sarcoma | 1 | 2003 | 203 | 0.040 |
Why?
|
| Fluoroscopy | 1 | 2021 | 175 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2025 | 1320 | 0.040 |
Why?
|
| Diastole | 5 | 2000 | 142 | 0.040 |
Why?
|
| KATP Channels | 1 | 2021 | 23 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2020 | 2012 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2020 | 1537 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 971 | 0.040 |
Why?
|
| Culture Media | 1 | 2021 | 161 | 0.040 |
Why?
|
| Diagnosis, Differential | 3 | 2012 | 1501 | 0.040 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2001 | 50 | 0.040 |
Why?
|
| Adrenergic alpha-Agonists | 2 | 1998 | 27 | 0.040 |
Why?
|
| Rituximab | 1 | 2021 | 211 | 0.040 |
Why?
|
| Surgery, Plastic | 1 | 2001 | 53 | 0.040 |
Why?
|
| Troponin I | 2 | 2011 | 72 | 0.040 |
Why?
|
| Lung Diseases | 2 | 2008 | 780 | 0.040 |
Why?
|
| Imidazoles | 1 | 2021 | 246 | 0.040 |
Why?
|
| Acidosis | 2 | 1998 | 105 | 0.040 |
Why?
|
| Infant | 5 | 2024 | 10011 | 0.040 |
Why?
|
| Infant, Premature | 1 | 2024 | 612 | 0.040 |
Why?
|
| Ryanodine | 2 | 1996 | 15 | 0.040 |
Why?
|
| Calcium Chloride | 2 | 1996 | 11 | 0.040 |
Why?
|
| Cerebrovascular Circulation | 1 | 2022 | 287 | 0.040 |
Why?
|
| Biomarkers | 3 | 2020 | 4248 | 0.040 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2001 | 131 | 0.040 |
Why?
|
| Acylation | 1 | 2019 | 30 | 0.040 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2000 | 45 | 0.040 |
Why?
|
| Graft Rejection | 1 | 2023 | 511 | 0.040 |
Why?
|
| Vocabulary, Controlled | 1 | 2020 | 47 | 0.040 |
Why?
|
| Dissection | 1 | 2020 | 55 | 0.040 |
Why?
|
| Transportation | 1 | 2000 | 54 | 0.040 |
Why?
|
| Pericardium | 1 | 2020 | 59 | 0.040 |
Why?
|
| Vinblastine | 2 | 1996 | 75 | 0.040 |
Why?
|
| Peptidoglycan | 2 | 2011 | 28 | 0.040 |
Why?
|
| Seizures | 1 | 2023 | 473 | 0.040 |
Why?
|
| Magnetic Phenomena | 1 | 2019 | 11 | 0.040 |
Why?
|
| Cyclic GMP | 2 | 1996 | 90 | 0.040 |
Why?
|
| Vasomotor System | 2 | 1997 | 46 | 0.040 |
Why?
|
| Centrifugation | 1 | 2019 | 27 | 0.040 |
Why?
|
| Noise | 1 | 2000 | 71 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2016 | 2113 | 0.040 |
Why?
|
| Blotting, Western | 2 | 2018 | 1160 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 1980 | 406 | 0.040 |
Why?
|
| Child, Preschool | 5 | 2024 | 11767 | 0.040 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2019 | 39 | 0.040 |
Why?
|
| Bias | 1 | 2000 | 197 | 0.040 |
Why?
|
| Methylation | 1 | 2019 | 241 | 0.040 |
Why?
|
| Writing | 1 | 2020 | 102 | 0.040 |
Why?
|
| Brucellosis | 1 | 1978 | 2 | 0.040 |
Why?
|
| Age Distribution | 1 | 2019 | 402 | 0.040 |
Why?
|
| Databases as Topic | 1 | 2018 | 71 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2019 | 386 | 0.040 |
Why?
|
| Sodium-Hydrogen Exchangers | 1 | 1998 | 22 | 0.040 |
Why?
|
| CpG Islands | 1 | 2019 | 161 | 0.040 |
Why?
|
| Patient Care Planning | 1 | 2020 | 168 | 0.040 |
Why?
|
| Brachiocephalic Trunk | 1 | 2018 | 11 | 0.040 |
Why?
|
| Thrombectomy | 1 | 2019 | 78 | 0.040 |
Why?
|
| Cell Nucleus | 2 | 2019 | 591 | 0.040 |
Why?
|
| RNA, Small Interfering | 2 | 2012 | 629 | 0.030 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2018 | 113 | 0.030 |
Why?
|
| Heterochromatin | 1 | 2019 | 66 | 0.030 |
Why?
|
| Operative Time | 1 | 2019 | 181 | 0.030 |
Why?
|
| Mice, Knockout, ApoE | 1 | 2018 | 11 | 0.030 |
Why?
|
| Extracellular Space | 2 | 2009 | 119 | 0.030 |
Why?
|
| Respiratory Function Tests | 1 | 2000 | 541 | 0.030 |
Why?
|
| Endocarditis, Bacterial | 1 | 1978 | 46 | 0.030 |
Why?
|
| Oxidants | 1 | 1998 | 103 | 0.030 |
Why?
|
| omega-N-Methylarginine | 1 | 1997 | 29 | 0.030 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2019 | 127 | 0.030 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1998 | 165 | 0.030 |
Why?
|
| Stents | 1 | 2022 | 557 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2014 | 193 | 0.030 |
Why?
|
| Hyperplasia | 2 | 2018 | 177 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 2019 | 207 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2009 | 363 | 0.030 |
Why?
|
| Consensus | 1 | 2020 | 475 | 0.030 |
Why?
|
| Cell Physiological Phenomena | 1 | 1997 | 19 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 2020 | 254 | 0.030 |
Why?
|
| Adenocarcinoma | 3 | 1970 | 919 | 0.030 |
Why?
|
| Premedication | 1 | 1997 | 44 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2021 | 447 | 0.030 |
Why?
|
| Walk Test | 1 | 2018 | 80 | 0.030 |
Why?
|
| Glipizide | 1 | 1997 | 6 | 0.030 |
Why?
|
| Lysine | 1 | 2019 | 271 | 0.030 |
Why?
|
| Matrilin Proteins | 1 | 2017 | 3 | 0.030 |
Why?
|
| Sp7 Transcription Factor | 1 | 2017 | 7 | 0.030 |
Why?
|
| Antagomirs | 1 | 2017 | 12 | 0.030 |
Why?
|
| Pressure | 4 | 2000 | 224 | 0.030 |
Why?
|
| Sclerosis | 1 | 2017 | 11 | 0.030 |
Why?
|
| Cycloheximide | 4 | 1997 | 42 | 0.030 |
Why?
|
| Algorithms | 2 | 2018 | 1839 | 0.030 |
Why?
|
| Quality Indicators, Health Care | 1 | 2020 | 335 | 0.030 |
Why?
|
| Sensitivity and Specificity | 3 | 2008 | 1990 | 0.030 |
Why?
|
| Purinergic P1 Receptor Agonists | 1 | 1997 | 7 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 1998 | 287 | 0.030 |
Why?
|
| Nitric Oxide Synthase | 1 | 1997 | 234 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 728 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2019 | 310 | 0.030 |
Why?
|
| Myocardial Stunning | 1 | 1996 | 4 | 0.030 |
Why?
|
| Thapsigargin | 1 | 1996 | 20 | 0.030 |
Why?
|
| Interleukin-8 | 2 | 2008 | 269 | 0.030 |
Why?
|
| NFATC Transcription Factors | 1 | 2017 | 94 | 0.030 |
Why?
|
| Colonic Neoplasms | 2 | 1970 | 256 | 0.030 |
Why?
|
| Pulmonary Circulation | 2 | 1996 | 429 | 0.030 |
Why?
|
| Carotid Artery Diseases | 1 | 1977 | 69 | 0.030 |
Why?
|
| Purinergic P1 Receptor Antagonists | 1 | 1996 | 10 | 0.030 |
Why?
|
| Logistic Models | 2 | 2013 | 2112 | 0.030 |
Why?
|
| Patient Care Management | 1 | 2017 | 56 | 0.030 |
Why?
|
| Hydrogen Peroxide | 1 | 1998 | 332 | 0.030 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2017 | 76 | 0.030 |
Why?
|
| Vasodilator Agents | 1 | 2018 | 329 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2023 | 985 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2017 | 292 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2017 | 172 | 0.030 |
Why?
|
| Lymphatic Metastasis | 2 | 2015 | 330 | 0.030 |
Why?
|
| Arginine | 1 | 1997 | 238 | 0.030 |
Why?
|
| Acute Disease | 3 | 2008 | 1029 | 0.030 |
Why?
|
| Neutrophil Activation | 1 | 1996 | 84 | 0.030 |
Why?
|
| Infant, Newborn | 3 | 2024 | 6387 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2017 | 334 | 0.030 |
Why?
|
| Wounds, Nonpenetrating | 1 | 1979 | 315 | 0.030 |
Why?
|
| Electric Countershock | 2 | 2014 | 127 | 0.030 |
Why?
|
| Automation | 1 | 2016 | 102 | 0.030 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2015 | 58 | 0.030 |
Why?
|
| Coronary Sinus | 1 | 2015 | 9 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2019 | 401 | 0.030 |
Why?
|
| Veterans | 3 | 2017 | 1614 | 0.030 |
Why?
|
| RAW 264.7 Cells | 1 | 2015 | 48 | 0.030 |
Why?
|
| Intraoperative Care | 1 | 1996 | 63 | 0.030 |
Why?
|
| Biomarkers, Tumor | 2 | 2016 | 1314 | 0.030 |
Why?
|
| Radiation Exposure | 1 | 2016 | 63 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 196 | 0.030 |
Why?
|
| Pulmonary Embolism | 1 | 1978 | 241 | 0.030 |
Why?
|
| Cell Line | 1 | 2021 | 2821 | 0.030 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2016 | 122 | 0.030 |
Why?
|
| Hemolysis | 1 | 2017 | 242 | 0.030 |
Why?
|
| Electrocardiography | 2 | 2014 | 663 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2016 | 350 | 0.030 |
Why?
|
| Risk Adjustment | 1 | 2015 | 85 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 532 | 0.030 |
Why?
|
| Neurologic Examination | 1 | 2015 | 131 | 0.030 |
Why?
|
| Anaphylaxis | 1 | 2016 | 102 | 0.030 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor | 1 | 2014 | 17 | 0.030 |
Why?
|
| Stress, Mechanical | 1 | 2017 | 494 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 339 | 0.030 |
Why?
|
| Macrophages, Alveolar | 1 | 1997 | 368 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 310 | 0.030 |
Why?
|
| Surgical Procedures, Operative | 1 | 1997 | 268 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2016 | 193 | 0.030 |
Why?
|
| Thrombelastography | 1 | 2015 | 176 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 1996 | 370 | 0.030 |
Why?
|
| Locomotion | 1 | 2015 | 101 | 0.030 |
Why?
|
| Femoral Artery | 1 | 2015 | 190 | 0.030 |
Why?
|
| Varicose Veins | 1 | 1974 | 16 | 0.030 |
Why?
|
| Oxidative Stress | 3 | 2014 | 1331 | 0.030 |
Why?
|
| Bone Marrow Cells | 1 | 2015 | 320 | 0.030 |
Why?
|
| Gene Transfer Techniques | 1 | 1995 | 185 | 0.030 |
Why?
|
| Protein Transport | 1 | 2015 | 436 | 0.030 |
Why?
|
| Gene Expression | 2 | 2009 | 1474 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 2015 | 178 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2015 | 881 | 0.030 |
Why?
|
| Cardiac Output, Low | 1 | 2014 | 53 | 0.030 |
Why?
|
| Thoracic Injuries | 1 | 1974 | 70 | 0.030 |
Why?
|
| Interleukin-1 | 1 | 1997 | 961 | 0.030 |
Why?
|
| Colorectal Surgery | 1 | 2013 | 30 | 0.030 |
Why?
|
| Autonomic Nervous System | 1 | 2014 | 79 | 0.030 |
Why?
|
| Renin-Angiotensin System | 1 | 2014 | 79 | 0.020 |
Why?
|
| Septal Occluder Device | 1 | 2014 | 37 | 0.020 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2014 | 151 | 0.020 |
Why?
|
| Heart Conduction System | 1 | 2014 | 95 | 0.020 |
Why?
|
| Temperature | 1 | 1997 | 675 | 0.020 |
Why?
|
| Mortality | 1 | 2016 | 376 | 0.020 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2014 | 109 | 0.020 |
Why?
|
| Ventricular Pressure | 2 | 2008 | 52 | 0.020 |
Why?
|
| Medical History Taking | 1 | 2013 | 117 | 0.020 |
Why?
|
| Microtubules | 1 | 1996 | 286 | 0.020 |
Why?
|
| Amino Acids, Aromatic | 1 | 2013 | 6 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2014 | 238 | 0.020 |
Why?
|
| Models, Biological | 1 | 2021 | 1807 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 1995 | 313 | 0.020 |
Why?
|
| Minocycline | 1 | 2013 | 22 | 0.020 |
Why?
|
| Transplantation, Autologous | 1 | 1994 | 296 | 0.020 |
Why?
|
| Pulmonary Veins | 1 | 1974 | 104 | 0.020 |
Why?
|
| Nerve Degeneration | 1 | 2013 | 48 | 0.020 |
Why?
|
| Pandemics | 1 | 2021 | 1693 | 0.020 |
Why?
|
| Prazosin | 3 | 1997 | 25 | 0.020 |
Why?
|
| Creatine | 1 | 2013 | 63 | 0.020 |
Why?
|
| Serrate-Jagged Proteins | 1 | 2012 | 27 | 0.020 |
Why?
|
| Jagged-1 Protein | 1 | 2012 | 22 | 0.020 |
Why?
|
| Proteomics | 1 | 2019 | 1182 | 0.020 |
Why?
|
| Insulin | 1 | 2023 | 2500 | 0.020 |
Why?
|
| Molecular Chaperones | 1 | 2014 | 181 | 0.020 |
Why?
|
| Benzophenanthridines | 3 | 1996 | 10 | 0.020 |
Why?
|
| Glutamine | 1 | 2013 | 108 | 0.020 |
Why?
|
| Pacemaker, Artificial | 1 | 2014 | 126 | 0.020 |
Why?
|
| Rectum | 2 | 2013 | 183 | 0.020 |
Why?
|
| Smoking | 1 | 2019 | 1466 | 0.020 |
Why?
|
| Dipeptides | 1 | 2012 | 56 | 0.020 |
Why?
|
| Alkaloids | 3 | 1996 | 28 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2017 | 668 | 0.020 |
Why?
|
| Computer Simulation | 1 | 1997 | 1017 | 0.020 |
Why?
|
| Computer Systems | 1 | 2012 | 55 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2012 | 135 | 0.020 |
Why?
|
| Alanine | 1 | 2013 | 170 | 0.020 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2012 | 76 | 0.020 |
Why?
|
| Cholecystectomy | 2 | 1977 | 60 | 0.020 |
Why?
|
| Heart Aneurysm | 1 | 2011 | 12 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2014 | 420 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2020 | 2417 | 0.020 |
Why?
|
| Hypertension | 1 | 2020 | 1259 | 0.020 |
Why?
|
| RNA, Messenger | 3 | 2015 | 2808 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2012 | 205 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2017 | 2177 | 0.020 |
Why?
|
| Myocardial Infarction | 2 | 1996 | 1209 | 0.020 |
Why?
|
| Lactic Acid | 1 | 2013 | 301 | 0.020 |
Why?
|
| Forecasting | 1 | 1993 | 391 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2003 | 2321 | 0.020 |
Why?
|
| Fibrinolytic Agents | 1 | 2014 | 288 | 0.020 |
Why?
|
| Monitoring, Intraoperative | 1 | 2011 | 64 | 0.020 |
Why?
|
| Medicaid | 1 | 2015 | 464 | 0.020 |
Why?
|
| Perioperative Period | 1 | 2011 | 70 | 0.020 |
Why?
|
| Heart Massage | 1 | 1971 | 11 | 0.020 |
Why?
|
| Medical Futility | 1 | 2011 | 31 | 0.020 |
Why?
|
| Desmin | 1 | 2010 | 24 | 0.020 |
Why?
|
| Constriction | 1 | 2011 | 46 | 0.020 |
Why?
|
| Pulmonary Edema | 1 | 2011 | 105 | 0.020 |
Why?
|
| Myosin Light Chains | 1 | 2010 | 26 | 0.020 |
Why?
|
| Disease Progression | 2 | 2015 | 2844 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2012 | 376 | 0.020 |
Why?
|
| Virginia | 1 | 2010 | 55 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2016 | 1880 | 0.020 |
Why?
|
| Angina Pectoris | 2 | 2001 | 75 | 0.020 |
Why?
|
| Cardiac Myosins | 1 | 2010 | 37 | 0.020 |
Why?
|
| Colon | 1 | 2013 | 307 | 0.020 |
Why?
|
| Health Services for the Aged | 1 | 2011 | 70 | 0.020 |
Why?
|
| Software | 1 | 2016 | 689 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 969 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2013 | 545 | 0.020 |
Why?
|
| Carcinoid Tumor | 1 | 1970 | 21 | 0.020 |
Why?
|
| Genes | 1 | 1990 | 226 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 1142 | 0.020 |
Why?
|
| Advance Directives | 1 | 2011 | 88 | 0.020 |
Why?
|
| Catheter Ablation | 1 | 2014 | 351 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2011 | 133 | 0.020 |
Why?
|
| Task Performance and Analysis | 1 | 2011 | 198 | 0.020 |
Why?
|
| Vascular Resistance | 1 | 2011 | 367 | 0.020 |
Why?
|
| Primates | 1 | 1990 | 132 | 0.020 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 1970 | 70 | 0.020 |
Why?
|
| Hospital Costs | 1 | 2010 | 125 | 0.020 |
Why?
|
| Professional-Family Relations | 1 | 2011 | 153 | 0.020 |
Why?
|
| Energy Metabolism | 1 | 1996 | 925 | 0.020 |
Why?
|
| Heart Septum | 1 | 2009 | 27 | 0.020 |
Why?
|
| Social Support | 1 | 2014 | 647 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 524 | 0.020 |
Why?
|
| Actinin | 1 | 2009 | 12 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2017 | 2485 | 0.020 |
Why?
|
| Transcriptome | 1 | 2016 | 1034 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 1405 | 0.020 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2009 | 37 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2014 | 726 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2010 | 364 | 0.020 |
Why?
|
| Emotions | 1 | 2014 | 575 | 0.020 |
Why?
|
| Polymerization | 1 | 2009 | 130 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2012 | 773 | 0.020 |
Why?
|
| Biopsy | 2 | 2011 | 1078 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2011 | 715 | 0.020 |
Why?
|
| Catalase | 2 | 2000 | 130 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2014 | 862 | 0.020 |
Why?
|
| Rectal Neoplasms | 1 | 1969 | 158 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 2741 | 0.020 |
Why?
|
| Antifungal Agents | 1 | 2009 | 149 | 0.020 |
Why?
|
| Stroke Volume | 1 | 2011 | 650 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2008 | 183 | 0.020 |
Why?
|
| Research | 1 | 2011 | 430 | 0.020 |
Why?
|
| Embolism, Fat | 1 | 1967 | 11 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2020 | 6035 | 0.020 |
Why?
|
| Peritoneal Cavity | 1 | 1967 | 30 | 0.020 |
Why?
|
| Random Allocation | 1 | 2008 | 364 | 0.020 |
Why?
|
| Probability | 1 | 2008 | 308 | 0.020 |
Why?
|
| Extracellular Matrix Proteins | 1 | 1988 | 155 | 0.020 |
Why?
|
| Decompression, Surgical | 1 | 2008 | 116 | 0.020 |
Why?
|
| Adrenergic alpha-Antagonists | 2 | 1997 | 34 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2014 | 880 | 0.020 |
Why?
|
| Hypoxia | 1 | 2014 | 1193 | 0.020 |
Why?
|
| Radiography | 3 | 1978 | 847 | 0.020 |
Why?
|
| Protein Synthesis Inhibitors | 2 | 1997 | 48 | 0.020 |
Why?
|
| Cartilage | 1 | 1988 | 198 | 0.020 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2007 | 142 | 0.020 |
Why?
|
| Cardiotonic Agents | 2 | 1997 | 94 | 0.020 |
Why?
|
| Pleura | 1 | 1986 | 28 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2010 | 733 | 0.020 |
Why?
|
| Precancerous Conditions | 1 | 2008 | 166 | 0.020 |
Why?
|
| Recurrence | 1 | 2010 | 1134 | 0.020 |
Why?
|
| Family | 1 | 2011 | 678 | 0.020 |
Why?
|
| Antibodies, Neutralizing | 1 | 2009 | 341 | 0.010 |
Why?
|
| Nitroprusside | 2 | 1996 | 71 | 0.010 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 2 | 1996 | 72 | 0.010 |
Why?
|
| Cytoplasm | 2 | 1997 | 257 | 0.010 |
Why?
|
| Hepatic Artery | 1 | 1966 | 53 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2012 | 1158 | 0.010 |
Why?
|
| Abdominal Injuries | 1 | 1967 | 129 | 0.010 |
Why?
|
| Leukocyte Count | 2 | 1996 | 315 | 0.010 |
Why?
|
| Enzyme Activation | 2 | 1998 | 762 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2008 | 847 | 0.010 |
Why?
|
| Gastroesophageal Reflux | 1 | 2008 | 236 | 0.010 |
Why?
|
| Cattle | 1 | 2008 | 971 | 0.010 |
Why?
|
| Acetylcholine | 2 | 1996 | 208 | 0.010 |
Why?
|
| Respiration, Artificial | 1 | 2010 | 709 | 0.010 |
Why?
|
| Necrosis | 2 | 1996 | 243 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2008 | 1246 | 0.010 |
Why?
|
| Biological Transport | 2 | 1996 | 416 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2007 | 475 | 0.010 |
Why?
|
| Binding Sites | 1 | 2008 | 1306 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 2940 | 0.010 |
Why?
|
| Muscle Proteins | 2 | 1996 | 240 | 0.010 |
Why?
|
| Communication | 1 | 2011 | 968 | 0.010 |
Why?
|
| Torsion Abnormality | 1 | 2003 | 20 | 0.010 |
Why?
|
| Vena Cava, Inferior | 1 | 2003 | 81 | 0.010 |
Why?
|
| Anemia, Hemolytic | 1 | 1982 | 16 | 0.010 |
Why?
|
| Florida | 1 | 1982 | 116 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2008 | 1809 | 0.010 |
Why?
|
| Surgery Department, Hospital | 1 | 2002 | 22 | 0.010 |
Why?
|
| Protein Binding | 1 | 2008 | 2241 | 0.010 |
Why?
|
| Eye | 1 | 1982 | 110 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2004 | 1263 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2011 | 1784 | 0.010 |
Why?
|
| Lipoproteins, HDL | 1 | 1980 | 99 | 0.010 |
Why?
|
| Quarantine | 1 | 2000 | 31 | 0.010 |
Why?
|
| Angiography | 1 | 1980 | 208 | 0.010 |
Why?
|
| Disease Outbreaks | 1 | 1982 | 422 | 0.010 |
Why?
|
| Brucella abortus | 1 | 1978 | 4 | 0.010 |
Why?
|
| Arm | 1 | 1979 | 110 | 0.010 |
Why?
|
| Amiloride | 1 | 1998 | 25 | 0.010 |
Why?
|
| Guanidines | 1 | 1998 | 36 | 0.010 |
Why?
|
| Calsequestrin | 1 | 1998 | 8 | 0.010 |
Why?
|
| Intestinal Absorption | 2 | 1969 | 103 | 0.010 |
Why?
|
| Reference Values | 1 | 2000 | 793 | 0.010 |
Why?
|
| Plasma Substitutes | 1 | 1998 | 5 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 1978 | 169 | 0.010 |
Why?
|
| Ileum | 2 | 1969 | 112 | 0.010 |
Why?
|
| Mast Cells | 1 | 1979 | 146 | 0.010 |
Why?
|
| Isotonic Solutions | 1 | 1998 | 42 | 0.010 |
Why?
|
| Sulfones | 1 | 1998 | 126 | 0.010 |
Why?
|
| Cytosol | 1 | 1998 | 213 | 0.010 |
Why?
|
| Embolism | 1 | 1978 | 48 | 0.010 |
Why?
|
| Organ Culture Techniques | 1 | 1997 | 149 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 1997 | 43 | 0.010 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2002 | 771 | 0.010 |
Why?
|
| Intracellular Membranes | 1 | 1997 | 76 | 0.010 |
Why?
|
| Maleimides | 1 | 1996 | 21 | 0.010 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 1 | 1996 | 18 | 0.010 |
Why?
|
| Permeability | 1 | 1997 | 168 | 0.010 |
Why?
|
| Infusions, Intra-Arterial | 1 | 1996 | 61 | 0.010 |
Why?
|
| Propranolol | 1 | 1996 | 44 | 0.010 |
Why?
|
| Sarcolemma | 1 | 1996 | 35 | 0.010 |
Why?
|
| Prostaglandin Endoperoxides, Synthetic | 1 | 1996 | 2 | 0.010 |
Why?
|
| Inositol 1,4,5-Trisphosphate | 1 | 1996 | 20 | 0.010 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 1 | 1996 | 4 | 0.010 |
Why?
|
| Pulse | 1 | 1996 | 27 | 0.010 |
Why?
|
| Thromboxane A2 | 1 | 1996 | 9 | 0.010 |
Why?
|
| Receptors, Thromboxane | 1 | 1996 | 4 | 0.010 |
Why?
|
| Transplantation Conditioning | 1 | 1997 | 185 | 0.010 |
Why?
|
| Calcimycin | 1 | 1996 | 36 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 1996 | 115 | 0.010 |
Why?
|
| Body Temperature | 1 | 1997 | 226 | 0.010 |
Why?
|
| Immune Sera | 1 | 1996 | 77 | 0.010 |
Why?
|
| Reperfusion | 1 | 1996 | 54 | 0.010 |
Why?
|
| Muscle Relaxation | 1 | 1996 | 28 | 0.010 |
Why?
|
| Diglycerides | 1 | 1996 | 59 | 0.010 |
Why?
|
| Linear Models | 1 | 1998 | 845 | 0.010 |
Why?
|
| Leg | 1 | 1978 | 239 | 0.010 |
Why?
|
| Swine | 1 | 1978 | 817 | 0.010 |
Why?
|
| Peroxidase | 1 | 1996 | 167 | 0.010 |
Why?
|
| Vasoconstrictor Agents | 1 | 1996 | 144 | 0.010 |
Why?
|
| Neutropenia | 1 | 1996 | 155 | 0.010 |
Why?
|
| Rabbits | 1 | 1996 | 646 | 0.010 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 1997 | 628 | 0.010 |
Why?
|
| Kinetics | 1 | 1998 | 1603 | 0.010 |
Why?
|
| Cineangiography | 1 | 1974 | 9 | 0.010 |
Why?
|
| Extracorporeal Circulation | 1 | 1974 | 14 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 1996 | 342 | 0.010 |
Why?
|
| Peripheral Vascular Diseases | 1 | 1995 | 104 | 0.010 |
Why?
|
| Collateral Circulation | 1 | 1974 | 19 | 0.010 |
Why?
|
| Chordae Tendineae | 1 | 1994 | 1 | 0.010 |
Why?
|
| Papillary Muscles | 1 | 1994 | 13 | 0.010 |
Why?
|
| Hemoptysis | 1 | 1974 | 35 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2003 | 1955 | 0.010 |
Why?
|
| Pleural Effusion | 1 | 1974 | 59 | 0.010 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 1996 | 623 | 0.010 |
Why?
|
| Muscle Contraction | 1 | 1996 | 429 | 0.010 |
Why?
|
| Action Potentials | 1 | 1996 | 501 | 0.010 |
Why?
|
| Indoles | 1 | 1996 | 500 | 0.010 |
Why?
|
| Ileostomy | 2 | 1969 | 26 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 1996 | 1098 | 0.010 |
Why?
|
| Drug Delivery Systems | 1 | 1995 | 379 | 0.010 |
Why?
|
| Thrombophlebitis | 1 | 1971 | 12 | 0.010 |
Why?
|
| Macaca nemestrina | 1 | 1990 | 29 | 0.010 |
Why?
|
| Papio | 1 | 1990 | 69 | 0.010 |
Why?
|
| Rats, Inbred Strains | 1 | 1990 | 320 | 0.010 |
Why?
|
| Pulmonary Fibrosis | 1 | 1974 | 392 | 0.000 |
Why?
|
| Tissue Distribution | 1 | 1990 | 333 | 0.000 |
Why?
|
| Species Specificity | 1 | 1990 | 572 | 0.000 |
Why?
|
| Oncogene Protein p55(v-myc) | 1 | 1988 | 1 | 0.000 |
Why?
|
| Oncogene Proteins v-raf | 1 | 1988 | 2 | 0.000 |
Why?
|
| Retroviridae Proteins | 1 | 1988 | 10 | 0.000 |
Why?
|
| Precipitin Tests | 1 | 1988 | 90 | 0.000 |
Why?
|
| Blotting, Northern | 1 | 1988 | 203 | 0.000 |
Why?
|
| Cell Line, Transformed | 1 | 1988 | 138 | 0.000 |
Why?
|
| Colectomy | 1 | 1969 | 106 | 0.000 |
Why?
|
| Pneumonia | 1 | 1974 | 627 | 0.000 |
Why?
|
| Proteoglycans | 1 | 1988 | 110 | 0.000 |
Why?
|
| Eating | 1 | 1990 | 388 | 0.000 |
Why?
|
| Oncogenes | 1 | 1988 | 118 | 0.000 |
Why?
|
| Protein Precursors | 1 | 1988 | 135 | 0.000 |
Why?
|
| Anuria | 1 | 1967 | 3 | 0.000 |
Why?
|
| Diatrizoate | 1 | 1967 | 2 | 0.000 |
Why?
|
| Blood Urea Nitrogen | 1 | 1967 | 53 | 0.000 |
Why?
|
| Tretinoin | 1 | 1988 | 124 | 0.000 |
Why?
|
| Lipase | 1 | 1967 | 75 | 0.000 |
Why?
|
| Cell Division | 1 | 1988 | 752 | 0.000 |
Why?
|
| Blood Gas Analysis | 1 | 1986 | 81 | 0.000 |
Why?
|
| Adipose Tissue | 1 | 1990 | 643 | 0.000 |
Why?
|
| Peritoneal Dialysis | 1 | 1967 | 99 | 0.000 |
Why?
|
| Vital Capacity | 1 | 1986 | 290 | 0.000 |
Why?
|
| Forced Expiratory Volume | 1 | 1986 | 448 | 0.000 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1970 | 1143 | 0.000 |
Why?
|
| Electrophoresis, Disc | 1 | 1980 | 3 | 0.000 |
Why?
|
| Cell Count | 1 | 1979 | 320 | 0.000 |
Why?
|
| Cholesterol | 1 | 1980 | 402 | 0.000 |
Why?
|
| Triglycerides | 1 | 1980 | 517 | 0.000 |
Why?
|
| Diarrhea | 2 | 1969 | 192 | 0.000 |
Why?
|
| Intestinal Mucosa | 2 | 1969 | 675 | 0.000 |
Why?
|
| Colitis, Ulcerative | 1 | 1969 | 148 | 0.000 |
Why?
|